Skip to content
DataLookout
Menu

3112 Ped BPDNCT04777357

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

StatusRecruiting
PhasePhase 3
SponsorAbbVie
Primary completion (estimated)

At risk: Enrollment reduced 11%.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 96 versions: 48 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 10 words
    • Primary endpoints: details revised at 1 of 9 entries
    • Enrollment reduced: 380 → 338 participants
    • Trial sites expanded: 81 → 87 locations
  2. Minor Site details revised at 1 of 81 sitesv94
  3. Minor Site details revised at 1 of 81 sitesv93
  4. Minor Site details revised at 1 of 81 sitesv92
  5. Minor Site details revised at 1 of 81 sitesv91
Show 43 earlier versionsHide 43 earlier versions
  1. Minor Site details revised at 1 of 81 sitesv90
  2. Minor Site details revised at 1 of 81 sitesv89
  3. Minor Site details revised at 3 of 81 sitesv88
  4. Minor Study sites: 80 to 81v87
  5. Minor Study sites: 79 to 80v86
  6. Minor Study sites: 78 to 79v85
  7. Minor Site details revised at 1 of 78 sitesv84
  8. Minor Study sites: 77 to 78v83
  9. Minor Study sites: 76 to 77v82
  10. Minor Study sites: 75 to 76v81
  11. Minor Study sites: 74 to 75v80
  12. Minor Site details revised at 1 of 74 sitesv79
  13. Minor Study sites: 73 to 74v78
  14. Minor Study sites: 72 to 73v77
  15. Minor Study sites: 71 to 72v76
  16. Minor Site details revised at 2 of 71 sitesv75
  17. Minor Site details revised at 2 of 71 sitesv74
  18. Minor Study sites revised (71)v73
  19. Minor Study sites: 70 to 71v72
  20. Minor Site details revised at 1 of 70 sitesv71
  21. Minor Study sites: 69 to 70v70
  22. Minor Site details revised at 1 of 69 sitesv69
  23. Minor Study sites: 68 to 69v68
  24. Minor Site details revised at 1 of 68 sitesv67
  25. Minor Site details revised at 1 of 68 sitesv66
  26. Minor Site details revised at 1 of 68 sitesv65
  27. Minor Primary and study completion dates: Mar 10, 2027 to Mar 2027v64
  28. Minor Study sites: 67 to 68v63
  29. Minor Study sites: 66 to 67v62
  30. Minor Site details revised at 1 of 66 sitesv61
  31. Minor Study sites: 63 to 66v60
  32. Notable Primary and study completion dates: Jan 29, 2025 to Mar 10, 2027
    • Primary endpoints: 5 to 9
    • Eligibility criteria expanded, about 4 words
    • Study sites: 58 to 63
    v59
  33. Minor Study sites: 57 to 58v58
  34. Minor Site details revised at 1 of 57 sitesv56
  35. Minor Study sites: 56 to 57v55
  36. Minor Study sites: 55 to 56v54
  37. Minor Study sites: 54 to 55v53
  38. Minor Study sites: 53 to 54v52
  39. Minor Study sites revised (53)v51
  40. Minor Study sites: 52 to 53v50
  41. Minor Study sites: 50 to 52v49
  42. Minor Site details revised at 1 of 50 sitesv48
  43. Notable Eligibility criteria expanded, about 31 words
    • Study sites: 49 to 50
    • Study title expanded, about 2 words
    v47
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with Adverse Events
Timeframe: Baseline (Week 0) to Week 10
Abnormal Change from Baseline in Vital Signs
Timeframe: Baseline (Week 0) to Week 10
Number of Participants with Incidence of Abnormal Clinical Laboratory Test Results
Timeframe: Baseline (Week 0) to Week 6
Change in Electrocardiogram (ECG)
Timeframe: Baseline (Week 0) to Week 6
Change From Baseline in Simpson-Angus Scale (SAS)
Timeframe: Baseline (Week 0) to Week 6
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: Baseline (Week 0) to Week 10
Change From Baseline in Barnes Akathisia Rating Scale (BARS)
Timeframe: Baseline (Week 0) to Week 6
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
Timeframe: Baseline (Week 0) to Week 6
Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score
Timeframe: Baseline (Week 0) to Week 6

Arms and interventions

PlaceboPlacebo comparator

Participants will receive Placebo over a 6 week treatment period.

CariprazineExperimental

Participants will receive flexible dose Cariprazine over a 6 week treatment period.

Drugs: Cariprazine, Placebo

Sites

87 sites in 3 countries

United States 75, Russia 10, Puerto Rico 2